Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of a PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (RHAPSODY)

NCT04494009 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04494009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04494009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of a PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (RHAPSODY)
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 7, 2020
Completion date
December 31, 2026
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer